The Zacks Analyst Blog Highlights: Amgen, Gilead, Celgene, Medivation and Biogen

Market data chart with calculator

For Immediate Release

Chicago, IL - May 05, 2016 - announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Amgen ( AMGN ), Gilead ( GILD ), Celgene ( CELG ), Medivation ( MDVN ) and Biogen ( BIIB ).

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free .

Here are highlights from Wednesday's Analyst Blog:

Biotech Stock Roundup

Earnings were the key focus this week with several major biotech companies like Amgen ( AMGN ), Gilead ( GILD ) and Celgene ( CELG ) reporting results. But in the midst of all this, acquisitions and deals continued to garner interest with Medivation ( MDVN ) confirming it got an unsolicited offer from Sanofi and Biogen ( BIIB ) deciding to spin-off its hemophilia business.

Recap of the Week's Most Important Stories

1. Big names in the biotech sector reported earnings over the last five trading days with some hitting the bull's eye and others falling short. Amgen started the year on the right note with not only a beat on all fronts but also a raised outlook (Read more: Amgen Tops Q1 Earnings & Revenues, Ups View ).

Meanwhile, pricing pressure and increasing competition is affecting sales of hepatitis C virus (HCV) products with both Gilead (Read more: Gilead Lags Q1 Earnings & Revenues, '16 View Intact ) and AbbVie recording a slowdown in HCV product sales. Vertex's first quarter results were also disappointing with the company missing estimates on earnings and revenues falling well short of expectations with Orkambi sales and guidance lagging expectations as well (Read more: Will Vertex Stock Decline on 1Q Earnings Miss? ).

Alexion's results also fell short of expectations (Read more: Alexion Lags Q1 Earnings & Revenues, Revises View ).

Celgene's results were mixed with an earnings beat and revenue miss ((Read more: Celgene Beats on Q1 Earnings, Updates '16 Outlook ).

2. AbbVie, known for its flagship product Humira, continues to sign deals to expand its pipeline and diversify its revenue base. Along with reporting first quarter results, the company said that it will be acquiring cancer drugmaker Stemcentrx. Rova-T, Stemcentrx's lead pipeline candidate, is currently in registrational studies for small cell lung cancer.

According to AbbVie, the candidate has blockbuster potential and could be launched in 2018. AbbVie intends to evaluate Rova-T for additional indications and estimates peak sales approaching $5 billion. (Read more: AbbVie Beats on 1Q Earnings, Lowers View on Deal )

3. Medivation confirmed last week that it received an unsolicited offer from French drugmaker Sanofi. However, Medivation's Board of Directors rejected the offer of $52.50 per share as not being in the best interests of the company and its shareholders. According to rumors, Sanofi is not the only company interested in acquiring Medivation. Companies like AstraZeneca, Pfizer, Gilead and Amgen are all rumored to be prospective suitors.

4. Biogen confirmed that it will be spinning off its hemophilia business into an independent, publicly traded company. There was quite a bit of speculation that the company would sell its hemophilia franchise which consists of Eloctate and Alprolix. Both products brought in total sales of $640 million during the twelve-month period ended Mar 31, 2016.

With the spin-off of this business, Biogen will go back to doing what it does best - developing and bringing neurology products to market. The company plans to speed up its efforts to bring new treatments for multiple sclerosis, spinal muscular atrophy (SMA), Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), and neuropathic pain to market.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today . Find out What is happening in the stock market today on

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

AMGEN INC (AMGN): Free Stock Analysis Report

GILEAD SCIENCES (GILD): Free Stock Analysis Report

CELGENE CORP (CELG): Free Stock Analysis Report

MEDIVATION INC (MDVN): Free Stock Analysis Report

BIOGEN INC (BIIB): Free Stock Analysis Report

To read this article on click here.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Other Topics


Latest Markets Videos


Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at

Learn More